Anke Vennegoor

1.2k total citations
24 papers, 824 citations indexed

About

Anke Vennegoor is a scholar working on Oncology, Pathology and Forensic Medicine and Electrical and Electronic Engineering. According to data from OpenAlex, Anke Vennegoor has authored 24 papers receiving a total of 824 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 16 papers in Pathology and Forensic Medicine and 9 papers in Electrical and Electronic Engineering. Recurrent topics in Anke Vennegoor's work include Multiple Sclerosis Research Studies (16 papers), Polyomavirus and related diseases (16 papers) and Full-Duplex Wireless Communications (9 papers). Anke Vennegoor is often cited by papers focused on Multiple Sclerosis Research Studies (16 papers), Polyomavirus and related diseases (16 papers) and Full-Duplex Wireless Communications (9 papers). Anke Vennegoor collaborates with scholars based in Netherlands, United States and China. Anke Vennegoor's co-authors include Joep Killestein, Bernard M.J. Uitdehaag, Chris H. Polman, Mike P. Wattjes, Frederik Barkhof, Theo Rispens, Bob W. van Oosten, Gertjan Wolbink, Alexandra Seewann and Eva Strijbis and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Analytical Biochemistry.

In The Last Decade

Anke Vennegoor

24 papers receiving 809 citations

Peers

Anke Vennegoor

PFM

ONCOL

EEE

IMMUN

NEURO

Nolan Campbell United States

Marion Wobser Germany

Raquel Planas Spain

Jai Perumal United States

Leoni Rolfes Germany

Simona Pontecorvo Italy

Gary J. Hoffman United States

Alexandra Schröder Germany

Amanda Charlton Australia

Sarah Rasia Italy

Nolan Campbell United States

Anke Vennegoor

503 ×1.0

PFM

363 ×0.7

ONCOL

50 ×0.3

EEE

109 ×0.7

IMMUN

137 ×1.0

NEURO

Citations per year, relative to Anke Vennegoor Anke Vennegoor (= 1×) peers Nolan Campbell

Countries citing papers authored by Anke Vennegoor

Since Specialization

Citations

This map shows the geographic impact of Anke Vennegoor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anke Vennegoor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anke Vennegoor more than expected).

Fields of papers citing papers by Anke Vennegoor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anke Vennegoor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anke Vennegoor. The network helps show where Anke Vennegoor may publish in the future.

Co-authorship network of co-authors of Anke Vennegoor

This figure shows the co-authorship network connecting the top 25 collaborators of Anke Vennegoor. A scholar is included among the top collaborators of Anke Vennegoor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anke Vennegoor. Anke Vennegoor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vennegoor, Anke, et al.. (2019). High work absence around time of diagnosis of multiple sclerosis is associated with fatigue and relapse rate. Multiple Sclerosis and Related Disorders. 31. 32–37. 12 indexed citations

Vennegoor, Anke, et al.. (2018). The fat embolism syndrome as a cause of paraplegia. SAGE Open Medical Case Reports. 6. 2050313X18789318–2050313X18789318. 3 indexed citations

Wijburg, Martijn T., Birgit I. Lissenberg‐Witte, Anke Vennegoor, et al.. (2016). MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. Journal of Neurology Neurosurgery & Psychiatry. 87(10). 1138–1145. 53 indexed citations

Vennegoor, Anke, Cyra E Leurs, Mike P. Wattjes, et al.. (2016). High cumulative JC virus seroconversion rate during long‐term use of natalizumab. European Journal of Neurology. 23(6). 1079–1085. 36 indexed citations

Wattjes, Mike P., Martijn T. Wijburg, Anke Vennegoor, et al.. (2015). MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. Journal of Neurology Neurosurgery & Psychiatry. 87(8). 879–884. 42 indexed citations

Vennegoor, Anke, et al.. (2015). Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy. Multiple Sclerosis Journal. 21(12). 1600–1603. 21 indexed citations

Wattjes, Mike P., Anke Vennegoor, Martijn D. Steenwijk, et al.. (2014). MRI pattern in asymptomatic natalizumab-associated PML. Journal of Neurology Neurosurgery & Psychiatry. 86(7). 793–798. 67 indexed citations

Wattjes, Mike P., Anke Vennegoor, Jop Mostert, et al.. (2014). Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?. Journal of Neurology. 261(6). 1139–1143. 26 indexed citations

Killestein, Joep, et al.. (2014). PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation. SHILAP Revista de lepidopterología. 2014. 1–4. 35 indexed citations

10.

Vennegoor, Anke, Theo Rispens, Bob W. van Oosten, et al.. (2014). Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy. Multiple Sclerosis Journal. 21(4). 481–484. 13 indexed citations

11.

Koel‐Simmelink, Marleen J.A., Anke Vennegoor, Joep Killestein, et al.. (2013). The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. Journal of Immunological Methods. 402(1-2). 43–49. 53 indexed citations

12.

Rispens, Theo, M. Hart, Pleuni Ooijevaar‐de Heer, et al.. (2013). Drug interference in immunogenicity assays depends on valency. Journal of Pharmaceutical and Biomedical Analysis. 85. 179–185. 16 indexed citations

13.

Vennegoor, Anke, et al.. (2013). Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients. Multiple Sclerosis Journal. 20(1). 108–111. 8 indexed citations

14.

Vennegoor, Anke, Theo Rispens, Eva Strijbis, et al.. (2012). Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Multiple Sclerosis Journal. 19(5). 593–600. 94 indexed citations

15.

Rispens, Theo, Astrid van Leeuwen, Anke Vennegoor, et al.. (2011). Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. Analytical Biochemistry. 411(2). 271–276. 55 indexed citations

16.

Ketelslegers, I. A., Piet W. Modderman, Anke Vennegoor, et al.. (2011). Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. Multiple Sclerosis Journal. 17(12). 1527–1530. 31 indexed citations

17.

Rispens, Theo, Anke Vennegoor, Gertjan Wolbink, Chris H. Polman, & Joep Killestein. (2011). Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Multiple Sclerosis Journal. 18(6). 899–901. 29 indexed citations

18.

Killestein, Joep, Anke Vennegoor, Eva Strijbis, et al.. (2010). Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated. Annals of Neurology. 68(3). 392–395. 99 indexed citations

19.

Voort, L.F. van der, Anke Vennegoor, Allerdien Visser, et al.. (2010). Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology. 75(14). 1228–1233. 31 indexed citations

20.

Kooij, Gijs, Jack van Horssen, Elizabeth C. M. de Lange, et al.. (2009). T lymphocytes impair P-glycoprotein function during neuroinflammation. Journal of Autoimmunity. 34(4). 416–425. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact